Skip to main content

Table 1 Patient and tumour characteristics of randomised patients

From: Women with large (≥3 cm) and locally advanced breast cancers (T3, 4, N1, 2, M0) receiving neoadjuvant chemotherapy (NAC: cyclophosphamide, doxorubicin, docetaxel): addition of capecitabine improves 4-year disease-free survival

 

GROUPS A + C (n = 57)

STATISTICAL SIGNIFICANCE*

GROUPS B + D (n = 55)

χ 2

p-value

Age in years, mean (range)

53.9 (33 – 69)

-

-

53.0 (35 – 69)

Menopausal status, n (%)

    

PRE-PERI

24 (42.1)

0.572

0.449

29 (52.7)

POST

33 (57.9)

  

26 (47.3)

TNM Classification, n (%)

    

T0-T1

2 (3.5)

  

1 (1.8)

T2

43 (75.4)

  

46 (83.6)

T3

5 (8.8)

4.881

0.300

5 (9.1)

T4

7 (12.3)

  

3 (5.5)

N0

32 (56.1)

  

29 (52.7)

N1-2

25 (43.9)

  

26 (47.3)

Tumour size in cm (caliper), mean (range)

4.3 (2 – 14)

-

-

4.2 (1.9 – 14)

Pre NAC nodal involvement, confirmed by biopsy, n (%)

22 (39.3)

-

-

23 (42.6)

Tumour type, n (%)

    

Ductal invasive

49 (86.0)

0.410

0.815

47 (85.5)

Lobular invasive (and others)

8 (14.0)

  

8 (14.5)

Tumour grade, n (%)

    

Grades 1 and 2

38 (66.7)

2.495

0.287

28 (51.0)

Grade 3

19 (33.3)

  

27 (49.0)

ER status, n (%)a

    

Positive (Allred >3)

45 (78.9)

1.732

0.421

37 (67.3)

Negative (Allred < 3)

12 (21.1)

  

12 (32.7)

HER2 status, n (%)b

    

Positive (FISH)

11 (19.3)

0.212

0.450

14 (25.9)

Negative

46 (80.7)

  

41 (74.1)

  1. aER : Oestrogen receptor. bHER2: Human epidermal growth factor receptor 2. Allred : Scoring system for measuring expression of oestrogen receptors in tissue sections. FISH : Fluorescence in-situ hybridisation.
  2. *Various patient and tumour characteristics were not significantly different between Groups (A + C) and (B + D) (p>0.05, Pearson Chi-Square Test).